Bergstrom; Carl P.
Patent Applications and Registrations
Patent applications and USPTO patent grants for Bergstrom; Carl P..The latest application filed is for "alpha-(n-sulfonamido)acetamide derivatives as beta-amyloid inhibitors".
- Bergstrom; Carl P. - Madison CT US
| Patent | Date |
|---|---|
| .alpha.-(N-sulfonamido)acetamide derivatives as .beta.-amyloid inhibitors Grant 8,513,253 - Parker , et al. August 20, 2 | 2013-08-20 |
| Compounds for the treatment of hepatitis C Grant 8,143,243 - Martin , et al. March 27, 2 | 2012-03-27 |
| Compounds for the treatment of hepatitis C Grant 8,133,884 - Martin , et al. March 13, 2 | 2012-03-13 |
| Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors App 20110105485 - Parker; Michael F. ; et al. | 2011-05-05 |
| .alpha.-(N-sulfonamido)acetamide derivatives as .beta.-amyloid inhibitors Grant 7,786,122 - Parker , et al. August 31, 2 | 2010-08-31 |
| Compounds for the treatment of hepatitis C Grant 7,652,004 - Martin , et al. January 26, 2 | 2010-01-26 |
| Compounds for the treatment of hepatitis C Grant 7,642,251 - Bergstrom , et al. January 5, 2 | 2010-01-05 |
| Compounds for the Treatment of Hepatitis C App 20090280083 - Martin; Scott W. ; et al. | 2009-11-12 |
| Compounds for the Treatment of Hepatitis C App 20090275561 - Martin; Scott W. ; et al. | 2009-11-05 |
| Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors Grant 7,521,441 - Gentles , et al. April 21, 2 | 2009-04-21 |
| Compounds for the Treatment of Hepatitis C App 20090074715 - Martin; Scott W. ; et al. | 2009-03-19 |
| Compounds for the Treatment of Hepatitis C App 20090042860 - Bergstrom; Carl P. ; et al. | 2009-02-12 |
| Indolobenzazepine HCV NS5B inhibitors Grant 7,473,688 - Bergstrom , et al. January 6, 2 | 2009-01-06 |
| Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors Grant 7,456,167 - Bergstrom November 25, 2 | 2008-11-25 |
| HCV NS5B inhibitors Grant 7,456,165 - Bergstrom , et al. November 25, 2 | 2008-11-25 |
| Alpha-(n-sulfonamido)acetamide Derivatives As Beta-amyloid Inhibitors App 20080085894 - Parker; Michael F. ; et al. | 2008-04-10 |
| Inhibitors of HCV replication Grant 7,348,425 - Hudyma , et al. March 25, 2 | 2008-03-25 |
| Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors App 20070275947 - Bergstrom; Carl P. | 2007-11-29 |
| .alpha.-(N-sulfonamido)acetamide derivatives as .beta.-amyloid inhibitors Grant 7,300,936 - Parker , et al. November 27, 2 | 2007-11-27 |
| Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors App 20070270406 - Gentles; Robert G. ; et al. | 2007-11-22 |
| HCV NS5B Inhibitors App 20070185083 - Bergstrom; Carl P. ; et al. | 2007-08-09 |
| Indolobenzazepine HCV NS5B inhibitors App 20070078122 - Bergstrom; Carl P. ; et al. | 2007-04-05 |
| Inhibitors of HCV replication Grant 7,153,848 - Hudyma , et al. December 26, 2 | 2006-12-26 |
| Inhibitors of HCV replication App 20060166964 - Hudyma; Thomas W. ; et al. | 2006-07-27 |
| Inhibitors of HCV replication App 20060046983 - Hudyma; Thomas W. ; et al. | 2006-03-02 |
| Sulfonamide compounds and uses thereof Grant 6,967,196 - Smith , et al. November 22, 2 | 2005-11-22 |
| Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors App 20040127494 - Parker, Michael F. ; et al. | 2004-07-01 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 